Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Memory boost for cocaine users? small study tests potassium channel blocker

NCT ID NCT07532460

First seen Apr 17, 2026 · Last updated Jun 23, 2026 · Updated 12 times

Summary

This study looks at whether a drug called fampridine, which blocks potassium channels in the brain, can improve working memory in people with cocaine use disorder. Forty chronic cocaine users will receive either the drug or a placebo and then take memory tests. The goal is to understand the brain mechanisms behind cognitive problems in cocaine users, not to test a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital of Psychiatry Zurich

    Zurich, Canton of Zurich, 8008, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

fampridine (4-aminopyridine)

What this could lead to

If it works, this could point toward a treatment for cognitive impairments in people with cocaine use disorder.

What could go wrong

This is a very small, early-stage study with only 40 participants. It tests a single dose, so any effects may be temporary or not translate to real-world benefits.

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.